+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Bacterial Meningitis Drug"

From
Bacterial Meningitis - Epidemiology Forecast to 2032 - Product Thumbnail Image

Bacterial Meningitis - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2024 - Product Thumbnail Image

Bacterial (Pyogenic) Meningitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Bacterial Meningitis is an infection of the membranes that cover the brain and spinal cord. It is caused by bacteria and can be life-threatening if not treated promptly. Treatment for bacterial meningitis typically involves antibiotics, which are drugs that target and kill the bacteria causing the infection. These drugs are part of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer's, Parkinson's, and epilepsy. The CNS drug market is highly competitive, with many companies developing and marketing drugs to treat neurological disorders. Some of the major players in the bacterial meningitis drug market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. These companies have developed a range of antibiotics to treat bacterial meningitis, including cephalosporins, penicillins, and fluoroquinolones. Show Less Read more